Influence of Lactobacillus paracasei HII01 Supplementation on Glycemia and Inflammatory Biomarkers in Type 2 Diabetes: A Randomized Clinical Trial

Abstract

It has been shown that gut dysbiosis can be associated with the development of type 2 diabetes mellitus (T2DM). Consequently, intervention with probiotics may be a useful approach to improve metabolic variables in diabetes. The present study aimed to evaluate the efficacy of L. paracasei HII01 on glycemia in T2DM patients. In a randomized, double-blind, placebo-controlled study, 50 participants were allocated to receive L. paracasei HII01 (50 × 109 CFU/day) or a placebo (corn starch 10 mg/day). Blood and fecal samples were assessed at baseline and at the end of the trial. After 12 weeks of intervention, fasting blood glucose level had significantly decreased in the probiotic group compared with the placebo group. Importantly, probiotic supplementation significantly decreased the plasma levels of LPS, TNF-α, IL-6 and hsCRP compared the placebo group. Additionally, an increase in beneficial bacteria and a decrease in pathogenic bacteria, which related to the improvement of SCFAs, was found following L. paracasei HII01 supplementation. These findings demonstrated that L. paracasei HII01 improved hyperglycemia and inflammatory markers by favorably modifying gut microbiota and subsequently ameliorating the leaky gut and endotoxemia, thereby suggesting a potential role as an adjuvant treatment in type 2 diabetes.

Probiotics Supplementation Improves Intestinal Permeability, Obesity Index and Metabolic Biomarkers in Elderly Thai Subjects: A Randomized Controlled Trial

“…The supplementation of L. paracasei HII01 (1.25 × 10 10 CFU per day) for 12 weeks did not significantly alter IgA's level [18]. The intervention of L. paracasei HII01 (5 × 10 10 CFU per day) for 12 weeks reduced the LPS, TNF-α, IL-6, and hsCRP levels in diabetic subjects [38]. Similarly, the supplementation of synbiotic preparation (L. paracasei HII01, B. longum, B. breve, inulin, and fructooligosaccharide) reduced LPS, TNF-α, IL-6, and hsCRP levels.…”

Microbiome First Medicine in Health and Safety

“…Table 4 illustrates examples from human clinical trials [ 131 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 175 , 176 , 177 , 178 , 179 , 180 , 181 , 182 , 183 ]. Not surprisingly, the best outcomes occur when there is a clear understanding of the specific microbes, genes, metabolic changes, and installation conditions that are needed to support microbiome-driven physiological benefits.…”

The Promising Role of Microbiome Therapy on Biomarkers of Inflammation and Oxidative Stress in Type 2 Diabetes: A Systematic and Narrative Review

“…The intestinal barrier is a semipermeable membrane that regulates the absorption of nutrients and electrolytes from the lumen into the blood stream, while preventing the entrance of infectious microorganisms as well as antigens, endotoxins, and proinflammatory substances ( 222 ). Intestinal permeability, therefore, is an intrinsic characteristic of the intestinal epithelium that allows for the exchange of luminal substances whilst maintaining an immunological barrier.…”